Biotech company Novavax announced that it is launching a Phase III trial of its covid-19 vaccine candidate in the U.S. and Mexico.
Two-thirds of the participants in the trial will randomly receive two intramuscular injections of the vaccine, administered 21 days apart, while one-third of the trial participants will receive a placebo.
The company said that it has selected around 100 trial sites in the U.S.
According to the statement from the company, Phases 1 and 2 trials of the vaccine candidate revealed that it was created a robust immune response. It also suggested a good tolerance generally.
Novavax is also currently conducting a large Phase 3 clinical study in the United Kingdom (U.K.), a Phase 2b safety and efficacy study in South Africa, and an ongoing Phase1/2 trial in the U.S. and Australia. Results from these trials are expected to come in as soon as early first quarter 2021, although timing could depend on transmission rates in the regions.